As Principal, Mr. Axe has extensive experience in both medical devices and pharmaceuticals across the biomedical industry. He is responsible for due diligence assessments and supports in transaction structuring of investment opportunities in the biopharmaceutical industry.
Mr. Axe joined NovaQuest Capital after 15 years at Eli Lilly and Co., where he held various positions including R&D Analytical Chemist, Project Management Advisor, Due Diligence Advisor, and most recently Due Diligence Advisor for Elanco Business Development. He was responsible for and led the corporate and scientific and technical due diligence evaluations associated with global transactions for in-licensing, out-licensing, divestitures, merger and acquisitions, as well as alternative deal structures. During his time at Lilly, Mr. Axe was also involved in drug repurposing efforts. His experience spans all therapeutic areas, all phases of developments, geographies and includes animal health.